Insulet (NASDAQ:PODD) Given New $185.00 Price Target at Benchmark

Key Points

• Benchmark lowered Insulet’s price target to $185 from $250 while maintaining a Buy rating, implying roughly 36% upside from the prior close. The broader analyst consensus is Hold, with an average target of $205.28.
• Insulet beat second-quarter expectations, reporting adjusted EPS of $1.66 and revenue of $801.7 million, with revenue up 23.5% year over year.
• Despite the earnings beat, the company reduced its 2026 revenue outlook amid slower U.S. insulin-pump sales and weaker Type 2 patient adoption, prompting several analysts to cut targets or downgrade the stock.

Insulet (NASDAQ:PODD - Get Free Report) had its price target lowered by investment analysts at Benchmark from $250.00 to $185.00 in a research report issued on Thursday,Benzinga reports. The firm currently has a "buy" rating on the medical instruments supplier's stock. Benchmark's price target suggests a potential upside of 35.68% from the stock's previous close.

A number of other brokerages have also issued reports on PODD. JPMorgan Chase & Co. restated a "neutral" rating and set a $152.00 price target (down from $275.00) on shares of Insulet in a research note on Thursday. Deutsche Bank Aktiengesellschaft started coverage on Insulet in a research report on Tuesday, June 23rd. They issued a "buy" rating and a $190.00 price objective on the stock. The Goldman Sachs Group reiterated a "buy" rating and set a $205.00 price target on shares of Insulet in a research report on Wednesday, May 27th. Royal Bank Of Canada set a $160.00 target price on shares of Insulet in a research report on Thursday. Finally, Piper Sandler reduced their price objective on Insulet from $360.00 to $210.00 in a research note on Wednesday, May 6th. Fifteen research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $205.28.

Insulet Trading Up 2.3%

PODD stock traded up $3.09 during mid-day trading on Thursday, reaching $136.35. The company had a trading volume of 1,352,775 shares, compared to its average volume of 1,298,864. The company has a market capitalization of $9.44 billion, a PE ratio of 31.75, a price-to-earnings-growth ratio of 1.16 and a beta of 1.10. The firm has a 50 day moving average of $155.56 and a 200 day moving average of $195.01. Insulet has a 12 month low of $126.40 and a 12 month high of $354.88. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.49 and a quick ratio of 1.81.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.47 by $0.19. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The firm had revenue of $801.70 million during the quarter, compared to analyst estimates of $787.39 million. During the same quarter in the previous year, the business earned $1.17 earnings per share. Insulet's quarterly revenue was up 23.5% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.460- EPS. On average, equities analysts predict that Insulet will post 6.45 earnings per share for the current fiscal year.

Insider Activity at Insulet

In related news, Director Timothy C. Stonesifer acquired 2,790 shares of Insulet stock in a transaction that occurred on Wednesday, June 3rd. The shares were purchased at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the acquisition, the director owned 9,041 shares in the company, valued at approximately $1,297,473.91. This represents a 44.63% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 0.36% of the stock is currently owned by company insiders.

Institutional Trading of Insulet

Hedge funds have recently made changes to their positions in the business. Mitsubishi UFJ Trust & Banking Corp lifted its position in Insulet by 26.5% during the 4th quarter. Mitsubishi UFJ Trust & Banking Corp now owns 43,921 shares of the medical instruments supplier's stock worth $12,484,000 after acquiring an additional 9,206 shares during the period. Asset Management One Co. Ltd. increased its holdings in shares of Insulet by 99.5% in the fourth quarter. Asset Management One Co. Ltd. now owns 76,594 shares of the medical instruments supplier's stock valued at $21,948,000 after purchasing an additional 38,193 shares during the period. OP Asset Management Ltd purchased a new stake in shares of Insulet during the first quarter worth approximately $1,513,000. Strs Ohio lifted its holdings in shares of Insulet by 36.0% during the fourth quarter. Strs Ohio now owns 22,680 shares of the medical instruments supplier's stock worth $6,447,000 after purchasing an additional 6,003 shares during the period. Finally, Swedbank AB grew its position in Insulet by 11.0% in the 4th quarter. Swedbank AB now owns 85,988 shares of the medical instruments supplier's stock valued at $24,441,000 after buying an additional 8,500 shares during the last quarter.

Key Insulet News

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet beat second-quarter expectations, reporting adjusted EPS of $1.66 versus the $1.47 consensus and revenue of $801.7 million versus estimates of $787.4 million. Revenue increased 23.5% year over year, supporting the view that the company’s underlying Omnipod growth remains solid. Reuters report on Insulet earnings
• Positive Sentiment: Stifel Nicolaus maintained a Buy rating and set a $180 price target, implying substantial upside from recent levels. The target was reduced from $225, however, limiting the bullish signal. Benzinga analyst target report
• Neutral Sentiment: JPMorgan reaffirmed its Neutral rating but cut its price target sharply to $152 from $275. The new target remains above the recent share price, but the reduction reflects materially lower expectations. Benzinga JPMorgan analyst report
• Negative Sentiment: Insulet lowered its 2026 revenue outlook to $3.2 billion-$3.3 billion, below the roughly $3.3 billion consensus, and provided third-quarter revenue guidance of $829.9 million-$844.0 million versus expectations of $846.3 million. Slower U.S. insulin-pump sales and weaker-than-expected adoption or retention among Type 2 patients are weighing on sentiment. Insulet guidance and Type 2 patient report
• Negative Sentiment: Leerink Partners downgraded PODD from Outperform to Market Perform with a $145 target, while Oppenheimer also moved the stock to Market Perform. These actions reinforce concerns that the earnings beat does not offset the softer outlook. The Fly analyst report
• Negative Sentiment: Several law firms publicized securities class-action claims alleging that Insulet misrepresented manufacturing quality and product safety before two Omnipod medical-device corrections. The allegations are not proven, but the litigation adds reputational, regulatory, and potential financial-risk concerns. The lead-plaintiff deadline is August 31, 2026. Insulet shareholder litigation alert

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company's core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet's products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company's product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source